Lytix Biopharma is rated 3 out of 5 in the category biotechnology. Read and write reviews about Lytix Biopharma. Lytix Biopharma is a private clinical-stage biotech company developing proprietary oncolytic peptides as a novel immune therapy to fight cancer. Lead compound LTX-315 provides access to antigens by using the patient’s own tumor as source of antigens and turns cold tumors hot. Local treatment with LTX-315 targets the first step in the cancer immunity cycle with a potential cornerstone position in immunotherapy.
Company size
1-10 employees